Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Tasly Pharmaceutical Group Co Ltd    600535   CNE000001C81

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Tasly Pharmaceutical Group Co Ltd : PPB Officials Visit Tasly (2013-09-29)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/30/2013 | 10:16pm CET

A group of 5 officials led by Dr. Mwaniki, an official at the Registrar of the Pharmacy and Poisons Board (PPB) of Kenya and chairman of Pharmaceutical Society of Kenya, visited Tasly on Aug. 19 and held wide-ranging talks with senior officers, including Tasly International CEO Bill Dai.

PPB Officials with Tasly International Management

A PPB Official Complimenting Guotai Liquor

Visiting the International Communication Center, the production monitoring room of Tasly Pharmaceutical, the manufacturing facility of T89, the plant of Tasly Cooperative and some cultural landscapes inside the industrial park, the guests gave unanimous approval of and complimentary remarks on the scale of Tasly, the professional manufacturing facilities and the stringent quality control. Later in talks with CEO Dai, the officials listened to a detailed introduction of Tasly's corporate strength and international marketing and tried the Guotai Liquor. They expressed the hope that Tasly would market its premium products like modernized TCM, pharmaceutical chemical and API in Kenya to benefit the native people and recommend Guotai Liquor to high-end consumers in the country.

Lying in eastern Africa, Kenya is one of the wealthy countries in this part of continent. The nation with a population around 40m has a relatively mature drug market and is the largest pharmaceutical manufacturing and distribution market of COMESA (Common Market for Eastern and Southern Africa). Nevertheless, API is highly dependent on import due to insufficient production. Besides, the poor medical conditions prevalent in Eastern Africa also contribute to Kenya's considerable demand for pharmaceutical products and development potential.

Tasly has already formulated plans on vigorous development of indirect selling of pharmaceutical chemicals, APIs and modernized TCM drugs in Kenya. This tour by PPB officials focused on investigation of Tasly's scale of business and manufacturing capacity was organized to boost the mutual understanding and trust between Tasly and competent Kenyan agencies and pave the way for future entry into the pharmaceutical distribution market of the country.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TASLY PHARMACEUTICAL GROUP
11/04 TASLY PHARMACEUTICAL : won Top 20 of Most Competitive Pharmaceutical Listed Comp..
08/15 TASLY PHARMACEUTICAL : H1 Net Down 17.5%
08/11 TASLY PHARMACEUTICAL : listed in Top 100 of Chinese Pharmaceutical Industry in 2..
07/29 TASLY PHARMACEUTICAL : Breakthrough in TCM Smart Manufacture Technology (2016-07..
04/01 TASLY PHARMACEUTICAL : 2016 Shareholders’ Committee, Board of Directors, a..
03/30 TASLY PHARMACEUTICAL : The Announcement of FDAⅢ Progress of Dantonic Pill ..
03/29 TASLY PHARMACEUTICAL : 2015 Net Up 8%
2015 TASLY PHARMACEUTICAL : The 26th China-US Joint Commission on Commerce and Trade ..
2015 TASLY PHARMACEUTICAL : Director of Board of Tasly Phar. Group Mr.Yan Kaijing won..
2015 TASLY PHARMACEUTICAL : 2015 Enterprise honors— Tasly Phar.'s digitized pro..
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ( CNY)
Sales 2016 13 693 M
EBIT 2016 1 984 M
Net income 2016 1 528 M
Debt 2016 1 562 M
Yield 2016 1,11%
P/E ratio 2016 30,29
P/E ratio 2017 25,69
EV / Sales 2016 3,48x
EV / Sales 2017 3,12x
Capitalization 46 061 M
More Financials
Chart TASLY PHARMACEUTICAL GROUP
Duration : Period :
Tasly Pharmaceutical Group Technical Analysis Chart | 600535 | CNE000001C81 | 4-Traders
Full-screen chart
Technical analysis trends TASLY PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 44,1  CNY
Spread / Average Target 3,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yong Hong Zhu General Manager & Director
Jian Zhong Zhang Chairman-Supervisory Board
Kai Jing Yan Chairman
Rui Hua Wang Chief Financial Officer
Xi Jun Yan Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TASLY PHARMACEUTICAL G..4.18%6 671
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
MERCK & CO., INC.15.92%168 820
More Results